It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Diabetic kidney disease is the main cause of end-stage renal disease worldwide. The prediction of the clinical course of patients with diabetic kidney disease remains difficult, despite the identification of potential biomarkers; therefore, novel biomarkers are needed to predict the progression of the disease. We conducted non-targeted metabolomics using plasma and urine of patients with diabetic kidney disease whose estimated glomerular filtration rate was between 30 and 60 mL/min/1.73 m2. We analyzed how the estimated glomerular filtration rate changed over time (up to 30 months) to detect rapid decliners of kidney function. Conventional logistic analysis suggested that only one metabolite, urinary 1-methylpyridin-1-ium (NMP), was a promising biomarker. We then applied a deep learning method to identify potential biomarkers and physiological parameters to predict the progression of diabetic kidney disease in an explainable manner. We narrowed down 3388 variables to 50 using the deep learning method and conducted two regression models, piecewise linear and handcrafted linear regression, both of which examined the utility of biomarker combinations. Our analysis, based on the deep learning method, identified systolic blood pressure and urinary albumin-to-creatinine ratio, six identified metabolites, and three unidentified metabolites including urinary NMP, as potential biomarkers. This research suggests that the machine learning method can detect potential biomarkers that could otherwise escape identification using the conventional statistical method.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 The University of Tokyo Graduate School of Medicine, Division of Nephrology and Endocrinology, Tokyo, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2151 536X)
2 Kyowa Kirin Co., Ltd., Tokyo, Japan (GRID:grid.473316.4) (ISNI:0000 0004 1789 3108); The University of Tokyo Graduate School of Medicine, Division of Chronic Kidney Disease Pathophysiology, Tokyo, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2151 536X)
3 Kyowa Kirin Co., Ltd., Tokyo, Japan (GRID:grid.473316.4) (ISNI:0000 0004 1789 3108)
4 Hitachi, Ltd., Research and Development Group, Tokyo, Japan (GRID:grid.417547.4) (ISNI:0000 0004 1763 9564)
5 Tokai University School of Medicine, Division of Nephrology, Endocrinology and Metabolism, Isehara, Japan (GRID:grid.265061.6) (ISNI:0000 0001 1516 6626)
6 The University of Tokyo Graduate School of Medicine, Division of Chronic Kidney Disease Pathophysiology, Tokyo, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2151 536X)